Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087071 · ClinicalTrials.gov registry record · Phase 2
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT03087071 is a Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 59 participants, below the 84-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03087071, a Phase 2 study of Metastatic Colorectal Adenocarcinoma and Stage IV Colorectal Cancer AJCC v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or without trametinib may work better in treating patients with stage IV colorectal cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Trametinib
- BIOLOGICAL Panitumumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-12-29 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03087071
The ClinicalTrials.gov registry entry for NCT03087071 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 14 other Metastatic Colorectal Adenocarcinoma trials with a reported enrollment target (30% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Metastatic Colorectal Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03087071 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03087071 about?
NCT03087071 is a clinical study titled "Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer". This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of t...
What is the current status of trial NCT03087071?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2017-12-29. Estimated completion is 2027-01-31.
What conditions does trial NCT03087071 study?
This clinical trial studies the following conditions: Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, KRAS Gene Mutation.
What interventions are being tested in trial NCT03087071?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Trametinib (DRUG), Panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03087071?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03087071 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
COMPLETED · Phase 2
-
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
RECRUITING · Phase 1
-
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Colorectal Adenocarcinoma
All registered trials for this condition
Stage IV Colorectal Cancer AJCC v7
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.